Investigation into the impact of a physical activity health promotion pack on the wellbeing of people living with cancer

A randomised waiting list control trial, with embedded process evaluation, to investigate the impact of a physical activity health promotion pack on the wellbeing of people living with cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN66418871

Enrollment

164

Registered

2017-07-26

Start date

2017-03-20

Completion date

Unknown

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

People living with cancer Cancer People living with cancer

Interventions

Participants are randomised using simple randomisation (toss of a coin) to either the intervention or the control group. Intervention arm: A printed physical activity health promotion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. People living with cancer 2. Aged 18 or over 3. Who can read English 4. Able to provide consent 5. Have an active e-mail account

Exclusion criteria

Exclusion criteria: 1. Those less than eight weeks post-surgery 2. Those experiencing extreme fatigue, anaemia or severe balance and coordination problems 3. Those with cancer in your bones, or bone thinning 4. Those with a heart or lung condition 5. Those experiencing pain in their chest at rest, during daily activities or when becoming active 6. Those experiencing persistent pain in their muscles, bones or joints 7. Those with swelling or inflammation in the abdomen, groin, or lower extremity 8. Those who have been informed by a doctor to only do medically supervised physical activity

Design outcomes

Primary

Measure	Time frame
Physical activity levels are measured using the Godin Leisure-Time Exercise Questionnaire at baseline, 12weeks, and 24 weeks.	—

Secondary

Measure	Time frame
1. Quality of life is measured using the FACT-G7 questionnaire at baseline, 12weeks, and 24 weeks 2. Self-efficacy is measured using a single-item measure based on a previous study (Kampshoff, van Mechelen, Schep, Nijziel and Witlox et al. (2016)) at baseline, 12weeks, and 24 weeks	—

Countries

United Kingdom

Contacts

Public ContactJustin Webb

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026